stockrowAlkermes plc
ALKS Healthcare Drug Manufacturers Specialty & Generic
Alkermes plc’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 5.25% from fiscal 2024.
- Revenue
- +21.8%
- EPS
- −80.6%
- Free cash flow
- +6.78%
Quarter to September 2026, against a year earlier
Follow ALKS
Alert me
Alkermes plc (ALKS) EBITDA
Alkermes plc's EBITDA for fiscal 2025 was $281.1M, down 37.4% from $449.2M in fiscal 2024. Over the twelve months to 30 September 2026 it was $217.3M. Over the past ten years it has ranged from −$138.7M (fiscal 2015) to $489.0M (fiscal 2023); the current reading is higher than 82% of that period. Alkermes plc ranks 18th of 80 Drug Manufacturers Specialty & Generic companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $281.1M | (37.41%) |
| FY2024 | $449.2M | (8.15%) |
| FY2023 | $489.0M | 581.38% |
| FY2022 | $71.8M | (59.31%) |
| FY2021 | $176.4M | — |
| FY2020 | −$30.6M | — |
| FY2019 | −$95.1M | — |
| FY2018 | $4.5M | — |
| FY2017 | −$49.4M | — |
| FY2016 | −$114.4M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $91.9M | 15.35% |
| Jun 2026 | $79.6M | — |
| Mar 2026 | −$16.1M | — |
| Dec 2025 | $62.0M | (36.24%) |
| 43 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| ELAN Elanco Animal Health Incorporated compare | $774.0M |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | $664.9M |
| SUPN Indivior Pharmaceuticals Inc. compare | $571.0M |
| RDY Dr. Reddy's Laboratories Ltd compare | $526.8M |
| LNTH Lantheus Holdings, Inc. compare | $386.4M |
| ALKS Alkermes plc | $217.3M |
| LQDA Liquidia Corporation compare | $170.3M |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $132.4M |
| HIMS Hims & Hers Health, Inc. compare | −$62.2M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on ALKS
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement